Skip to main content

Lake Street Keeps Their Buy Rating on Achieve Life Sciences (ACHV)

Tipranks - Tipranks - Sat Nov 8, 2025

Lake Street analyst Thomas Flaten maintained a Buy rating on Achieve Life Sciences today and set a price target of $11.00.

Meet Your ETF AI Analyst

According to TipRanks, Flaten is a 5-star analyst with an average return of 18.0% and a 54.15% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Insight Molecular Diagnostics, and Harrow Health.

Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $14.60.

See Insiders’ Hot Stocks on TipRanks >>

Based on Achieve Life Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $14.44 million. In comparison, last year the company had a GAAP net loss of $12.51 million

Read More on ACHV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).